ROSEN, SKILLED INVESTOR COUNSEL, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KMXNovember 12, 2025 4:42 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the "Class Period") of the i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [2][5]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates [5]. - It is claimed that Telix materially overstated the quality of its supply chain and partners, leading to misleading statements about its business and operations [5]. - The lawsuit asserts that when the true details emerged, investors suffered damages, particularly following significant announcements from the company [5]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of its American Depositary Shares to drop over 13% in two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in its Chemistry, Manufacturing, and Controls package, leading to a further decline of over 21% in its ADS price [7]. Group 3: Legal Proceedings and Investor Participation - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Telix is January 9, 2026 [2]. - The lead plaintiff is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Faruqi & Faruqi encourages anyone with information regarding Telix's conduct to come forward, including whistleblowers and former employees [9].

Core Points - A class action securities lawsuit has been filed against James Hardie Industries plc, targeting alleged securities fraud that affected shareholders between May 20, 2025, and August 18, 2025 [2][3] - The lawsuit claims that the company made false statements and concealed negative facts regarding its North America segment, including deteriorating consumer demand and excessive inventory issues [3] Company Details - The complaint alleges that the primary driver of growth in the North America segment was overstocking rather than genuine consumer demand, leading to excessive inventory at distributors [3] - The lawsuit seeks to recover losses for shareholders who were adversely affected during the specified time frame, regardless of whether they still hold their shares [4] Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, is representing the shareholders in this case, boasting a strong track record in securing recoveries for aggrieved investors [5]

Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. regarding alleged violations of federal securities laws related to misleading statements about the Inspire V device launch [3][6] - Investors who suffered losses from August 6, 2024, to August 4, 2025, are encouraged to contact the firm to discuss their legal options before the January 5, 2026, deadline for seeking lead plaintiff status in a federal securities class action [2][3] Company Performance - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [7] - The company faced billing and reimbursement challenges, with necessary software updates for claims processing not effective until July 1, 2025, leading to continued use of the older Inspire IV system [7] - Demand for the Inspire V device was reported as weak, resulting in excess inventory and a drastic cut in 2025 earnings guidance by over 80% [8] Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, erasing approximately $1.2 billion in market capitalization [8]

San Diego, California--(Newsfile Corp. - November 12, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., No. 25-cv-0 ...

Core Insights - Valens Semiconductor Ltd. (NYSE: VLN) reported Q3 2025 revenue of $17.3 million, exceeding guidance of $15.1-$15.6 million, marking the sixth consecutive quarter of growth [1][8] - The GAAP gross margin was 63.0% and non-GAAP gross margin was 66.7%, both above guidance, although slightly down from 63.5% in Q2 2025 [1][8] - Adjusted EBITDA loss was $(4.3) million, better than the expected range of $(7.4)-$(6.8) million [1][8] Financial Performance - Q3 2025 revenue of $17.3 million, up from $17.1 million in Q2 2025 and $16.0 million in Q3 2024 [1][8] - Management guided Q4 2025 revenue to be between $18.2 million and $18.9 million, with full-year growth expected to be near 20% year-over-year [1][8] - The company ended the quarter with $93.5 million in cash and no debt [1][8] Market Outlook - The company faces headwinds from tariff impacts, particularly in the automotive sector [1] - Despite mixed visibility into year-end, steady growth is expected through 2026 as ProAV normalizes and machine vision and medical programs ramp up, with automotive stabilizing alongside ongoing A-PHY ecosystem progress [1]

Core Viewpoint - Restart Life Sciences Corp. is initiating a non-brokered private placement to raise up to CAD $1,000,000 through the sale of 10,000,000 units at CAD $0.10 each, aimed at advancing its initiatives in brain health and wellness [1][3]. Group 1: Offering Details - The private placement will consist of units, each including one common share and one transferable common share purchase warrant, allowing the holder to purchase an additional common share at CAD $0.10 for one year [2]. - The total gross proceeds from the offering are expected to be up to CAD $1,000,000 [1]. Group 2: Use of Proceeds - The funds raised will be allocated towards health food trials, potential acquisitions, and general working capital [4]. - The company is focused on progressing its initiatives in brain health and overall wellness, which will be supported by this financing [3]. Group 3: Company Overview - Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the Canadian Securities Exchange [5].

ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 12, 2025 4:21 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Per ...

Core Insights - Burcon NutraScience Corporation reported strong operational execution and growing commercial traction in the plant-based protein sector, reaffirming its revenue targets for 2025 and 2026 [2][3][6] Operational Highlights - Burcon has over 200 active customer projects, with many nearing completion, indicating a rapid scaling of demand and transition to recurring commercial sales [4] - The company successfully commercialized its technology for canola and fava protein production at its Galesburg facility [3] - Recent production runs have been allocated to innovative food and beverage companies, showcasing broad customer adoption [5] Financial Performance - For the fiscal second quarter ended September 30, 2025, Burcon generated revenues of $357,000, representing a 783% increase year-over-year [7] - The company reported a net loss of $7.1 million, compared to a loss of $4.2 million in the same period last year, driven by increased costs associated with production [9] - Cash used in operating activities increased to $4.6 million from $3.0 million in the prior year [9] Future Outlook - Burcon aims to achieve a revenue target of over $10 million for calendar 2026, supported by strong market validation and a diversified protein portfolio [6] - The company is focused on strengthening customer partnerships and scaling production to meet global demand [6] Financial Position - As of September 30, 2025, Burcon had $1.8 million in cash and a negative working capital of $8.2 million, primarily due to a senior secured loan from a related party [10] - The company has taken steps to improve its financial position, including obtaining a $0.7 million short-term loan and launching a convertible debenture offering for up to $4 million [10]

Core Points - Adelayde Exploration Inc. is conducting a non-brokered flow-through private placement to raise up to $1,000,000 at a price of $0.13 per unit and a non-flow-through private placement to raise up to $1,500,000 at a price of $0.10 per unit [1] - The flow-through units will consist of one flow-through common share and one transferable share purchase warrant, while the non-flow-through units will consist of one common share and one transferable share purchase warrant [1] - Proceeds from the flow-through shares will be allocated to the company's existing properties in Canada, while net proceeds from the non-flow-through private placement will be used for general working capital [1] Financial Details - The flow-through private placement aims to raise $1,000,000, while the non-flow-through private placement targets $1,500,000 [1] - Each flow-through unit includes a warrant to purchase a non-flow-through common share at $0.25 for two years, and each non-flow-through unit includes a warrant to purchase a common share at $0.20 for five years [1] Regulatory Information - All securities issued in connection with the private placements will be subject to a statutory hold period of four months and one day after closing [1] - Finder's fees may be paid to eligible finders in connection with the private placements [1]